Platform

KCI Early Toxicology Platform (non-GLP toxicology platform) focuses on providing rapid and flexible preclinical toxicity assessment services for drug research and development companies to help them efficiently screen candidate molecules in the drug discovery and lead compound optimization phases, and to lay a solid foundation for the subsequent GLP toxicology studies and IND (Application for Clinical Trials of New Drugs) filing. By integrating in vitro models, in vivo short-term toxicity experiments and other technologies, the platform provides multi-dimensional early safety data to help customers quickly identify potential toxicity risks, optimize compound structures and reduce R&D failure rates.